Dr Dawn A Firmin BSc, MSc, PhD

Head of Project Management

Dr Dawn Firmin is responsible for planning, managing and executing the pharmaceutical development of the Company’s programmes and providing leadership to the project teams.

Dawn is a scientific professional with 10 years of combined experience in immunology & infection, toxicology management and the management of drug development of NCEs. Dawn’s expertise lies in her knowledge and experience of managing all preclinical and Phase I activities of the drug development process, including pre-IND meetings.

Dawn was a Post-Doctoral Immunology Research Scientist at the University of Glasgow specialising in a mechanistic in vivo model of Ankylosing Spondylitis. Prior to this she worked for one of the leading Contract Research Organisations, Charles River Laboratories, where she was a Senior Assistant Scientist and Project Manager of toxicology studies. Before joining CRL, she completed her PhD in Immunology and Infection at the University of Aberdeen. Prior to completing her PhD, Dawn also gained an MSc in Medical Diagnostics and graduated from the University of Stirling with a 2.1 Honours degree in Ecology.  She has authored and co-authored academic papers and is a member of the Scottish Life Science Association.

Dr Miroslav Ravic MD, PhD

Chief Executive Officer, Chief Science Officer & Chief Medical Officer

Dr Ravic has 30 years of experience covering clinical practice, medical science and drug development of biologics and small molecules. He has a PhD in Clinical Pharmacology from London University, an MD, and an MSc in Experimental Pharmacology with specialisation in Clinical Pharmacology from the University of Belgrade.

He has authored and presented numerous scientific papers. His previous posts include senior development positions at Boehringer Ingelheim, Eisai Europe and Antisoma in London. Dr Ravic has completed around 100 clinical trials and specialises in bridging the transition from preclinical to clinical development, having created a proven methodology for increasing speed and reducing costs to achieve proof of concept.

Mr Raymond Spencer ACA

Chief Financial Officer

Raymond Spencer has over 25 years experience as a senior financial officer in biotech. For 12 years he was the CFO of LSE listed Antisoma plc. Whilst at Antisoma he was instrumental in completing the IPO in 1998, and in several fund-raising rounds, totalling over £100 million, as well as the acquisition of two private biotech companies. He was also instrumental in the closing of three licensing deals with big pharma.